PATENT CLAIM ANALYSIS

Application Number: 15745714
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["549", "022000"]

Abstract:
The invention relates to Pro-drugs, comprising red-ox-sensitive cleavage sites. The compounds may be utilized in medical practice for targeting of si RNA, antisense oligonucleotides or protein-based therapeutics to the cytoplasmatic compartment of cells both in vitro or in vivo, in a subject in need.

Claim (Index 1):
A Pro-drug, comprising the structure as set forth in general Formula (Ia) or Formula (Ib): including pharmaceutically acceptable salts, hydrates, solvates and metal chelates of the compounds represented by the structures as set forth in Formula (Ia) or Formula (Ib), and solvates and hydrates of the salts, wherein: m and n, each stands for an integer, independently selected from 0, 1, 2, 3 or 4; A is selected from null; \u2014CH\u2014, \u2014N\u2014, \u2014CH 2 \u2014CH\u2014; \u2014CH 2 \u2014N\u2014; \u2014NH\u2014CH\u2014; \u2014S\u2014CH\u2014; \u2014O\u2014CH\u2014; Q 1 , Q 2 , Q 3  or Q 4  may be the same or different, and are each independently selected from null, hydrogen, hydroxyl, amine group, a nitro group, a sulfonyl group, a halogen atom, a fluorocarbon group; a carbonyl group \u2014C(\u2550O)\u2014; an amide group [\u2014C(\u2550O)\u2014NH\u2014; \u2014HN\u2014C(\u2550O)\u2014]; \u2014O\u2014C(\u2550O); \u2014C(\u2550O)\u2014O\u2014; a thioester group [\u2014C(\u2550O)\u2014S\u2014; \u2014S\u2014C(\u2550O)\u2014]; a thionoester group \u2014O\u2014C(\u2550S); \u2014C(\u2550S)\u2014O\u2014; wherein if Q 1  is hydrogen, hydroxyl, a nitro group, a sulfonyl group, a halogen atom, a fluorocarbon group, then Q 3  is different from any one of hydrogen, hydroxyl, a nitro group, a sulfonyl group, a halogen atom, a fluorocarbon group; and wherein if Q 3  is hydrogen, hydroxyl, a nitro group, a sulfonyl group, a halogen atom, or a fluorocarbon group, then Q 1  is different from any one of hydrogen, hydroxyl, a nitro group, a sulfonyl group, a halogen atom, a fluorocarbon group; L 1 , L 2 , L 3  and L 4  may be the same or different, and are each independently selected from null, hydrogen, or from the group consisting of:\n linear, cyclic or branched C 1 , C 2 , C 3 , C 4 , C 5  alkyl or hetero-alkyl; \n linear, cyclic or branched C 2 , C 3 , C 4 , C 5 , C 6 , alkylene or heteroalkylene; and \n C 5 , C 6 , C 7 , C 8 , C 9 , C 10  aryl or heteroaryl; \n wherein if L 1  is hydrogen then L 3  and L 4  are different than hydrogen and wherein if L 3  is hydrogen than L 1  and L 2  are different than hydrogen; and wherein if L 2  is either null or hydrogen, then L 4  is not null or hydrogen; and if L 4  is either null or hydrogen then L 2  is not null or hydrogen. * is an optional attachment point of chemical moieties Y and Z, wherein the Pro-drug may include Y, Z or both, and wherein Y and Z each being a subunit of the pro-drug, destined to be separated and released upon its cleavage; and wherein Y and Z may be identical or different.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.28947
- Patent Class: 549.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15691821', '15222559', '14872179', '14830799', '10585928']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7324433783321076
- 35 USC 102 Novelty (BERT): 0.5094479610065349
- Combined Prediction Score: 0.7101438365995504
- Mean Citation Score: 271.216316
- Max Citation Score: 300.4459
- Similarity Product: 239.5086020682276

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test